Cogent Biosciences Newsroom

J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21

Moomoo NewsNov 14 07:32 ET

LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 13 07:31 ET

Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsNov 13 06:31 ET

Cogent Biosciences Is Maintained at Buy by Needham

Dow JonesNov 13 05:46 ET

Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15

Moomoo NewsNov 13 05:38 ET

Cogent Biosciences Analyst Ratings

BenzingaNov 13 05:36 ET

Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position

TipRanksNov 13 05:31 ET

LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 5 15:31 ET

Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsNov 5 15:31 ET

Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences

TipRanksNov 5 13:57 ET

Cogent Biosciences Analyst Ratings

BenzingaNov 4 06:49 ET

H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17

Moomoo NewsNov 4 06:33 ET

Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsOct 24 05:33 ET

Cogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy Rating

TipRanksOct 24 05:25 ET

Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $15

Moomoo NewsSep 24 07:33 ET

Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)

TipRanksSep 24 06:52 ET

Cogent Biosciences Analyst Ratings

BenzingaSep 5 07:32 ET

A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $13 to $22

Moomoo NewsSep 4 09:00 ET

Hold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated Milestones

TipRanksAug 9 06:57 ET

JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19

BenzingaAug 7 14:07 ET